Chemistry:Tifluadom
 | |
| Clinical data | |
|---|---|
| Routes of administration | unknown |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H20FN3OS |
| Molar mass | 393.48 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Tifluadom is a benzodiazepine derivative with an unusual activity profile.[1] Unlike most benzodiazepines, tifluadom has no activity at the GABAA receptor, but instead is a selective agonist for the κ-opioid receptor.[2] It has potent analgesic[3] and diuretic[4] effects in animals, and also has sedative effects and stimulates appetite.[5][6]
While tifluadom has several effects which might have potential uses in medicine, such as analgesia and appetite stimulation, κ-opioid agonists tend to produce undesirable effects in humans such as dysphoria and hallucinations, and so these drugs tend to only be used in scientific research. Dysphoric effects are similar to those seen when using other κ-opioid receptor agonists like pentazocine and salvinorin A, and can be considered the opposite of morphine-induced euphoria. As such, kappa agonists are believed to have very limited abuse potential.
See also
- Lufuradom
- GYKI-52895, a benzodiazepine which is a dopamine reuptake inhibitor without GABAergic function
- GYKI-52,466, a benzodiazepine which is an AMPAkine and glutamate antagonist without GABAergic function
References
- ↑ Zeugner H, Roemer D, Liepmann H, Milkowski W, "2-Acylaminomethyl-1,4-benzodiazepine derivatives and their salts and pharmaceutical compositions thereof", US patent 4325957, issued 20 April 1982, assigned to Abbott Products GmbH
- ↑ "Unexpected opioid activity in a known class of drug". Life Sciences 31 (12–13): 1217–20. 1982. doi:10.1016/0024-3205(82)90346-0. PMID 6292610.
- ↑ "Tifluadom's effects under electric shock titration and tail-immersion procedures in squirrel monkeys". Life Sciences 39 (19): 1713–9. November 1986. doi:10.1016/0024-3205(86)90089-5. PMID 3773641.
- ↑ "Kappa opioid agonists and antagonists: effects on drinking and urinary output". Appetite 5 (1): 7–14. March 1984. doi:10.1016/s0195-6663(84)80044-6. PMID 6091543.
- ↑ "The role of opioid receptor sub-types in tifluadom-induced feeding". The Journal of Pharmacy and Pharmacology 36 (10): 683–6. October 1984. doi:10.1111/j.2042-7158.1984.tb04843.x. PMID 6150086.
- ↑ "Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects.". Journal of Pharmacology and Experimental Therapeutics 242 (2): 413–20. August 1987. PMID 3612543. http://jpet.aspetjournals.org/content/242/2/413.short.
 |  |
